HCPLive

12/25/2025

From baricitinib and upadacitinib data to emerging IL-2 and IL-7 pathway therapies, 2025 brought major momentum in .💡 Check out the most notable headlines in hair loss management in our Year in Review article. 🔗View here: https://hubs.li/Q03Z0tC00

12/25/2025

Once limited in options, HAE now has 12 FDA-approved therapies. Experts Daniel Soteres, MD, PhD, from University of Colorado Health Sciences Center, Raffi Tachdjian, MD, MPH, from UCLA Health, & Michael Manning, MD, an allergist based in Arizona, discuss 3 recent HAE approvals. https://hubs.li/Q03Z0tGy0

12/24/2025

As the year comes to a close, we’re grateful for the healthcare professionals who inspire us every day. Wishing you a joyful holiday season and a healthy, bright year ahead. Happy holidays. 🎄✨

12/24/2025

Between the rapid progression of olezarsen for hypertriglyceridemia and inclisiran's label update as a first-line therapy for hypercholesterolemia, lipid management has evolved substantially over 2025. Catch up on some of the most impactful news with our Year in Review.

Read now: https://hubs.li/Q03YZQk30

12/24/2025

The HCPLive team is covering some of the biggest medical news from 2025. Check out our stories from This Year in Medicine now.

This Year In Medicine | HCPLive is a clinical news and information portal, offering physicians specialty and disease-specific resources, conference coverage, and interviews.

12/24/2025

Could a less invasive biomarker help track IgA nephropathy activity? Podometrics is emerging as a promising pre-biopsy tool, according to new research. Learn more here: https://hubs.li/Q03YZQ0B0

12/24/2025

ICYMI: The FDA approved Nordisk’s semaglutide (Wegovy) pill as the first oral GLP-1 medicine for obesity in the US.

"With more choices, HCPs are better equipped to tailor treatment approaches and support patients who want to gain control of their weight, and this milestone approval underscores exactly that kind of choice," Timothy Garvey, MD, professor of medicine and director of the Diabetes Research Center at the University of Alabama at Birmingham, said in a statement. "The availability of [semaglutide] pill expands the possibilities for weight management with semaglutide, giving healthcare professionals a powerful, efficacious medicine in a new method of delivery, allowing the ability to help meet more patients where they are."

Learn more: https://hubs.li/Q03YZNZG0

12/24/2025

From pediatric approvals to fast-track biologics and late-stage trial readouts, 2025 was a milestone year for . Catch the biggest and research updates in our Year in Review 👇
https://hubs.li/Q03YZNWS0

12/24/2025

A new era in treatment is here. Experts Ruchi Gupta, MD & Edwin Kim, MD highlight advances in multi-allergen and sublingual approaches. https://hubs.li/Q03YZPRc0

12/23/2025

What’s next in the prevention and treatment of hepatic
encephalopathy? This expert-led, on-demand program unpacks
key challenges in managing OHE in cirrhosis and highlights
new research into unmet needs, biomarker development, and
investigational therapies. Watch Now: bit.ly/4opE2pg

12/23/2025

ITP is characterized by complex immune dysregulation that can lead to platelet loss and symptomatic burden. Explore how these mechanisms can inform comprehensive treatment approaches like multi-immune modulation to help manage the root causes of disease.

by Sanofi

Read More: bit.ly/4b4dOVi

12/23/2025

In the latest episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the recently released Libre Assist - a program designed to predict the glucose impact of any meal.

Watch now: https://hubs.li/Q03YVyqN0